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Preface
It is almost commonplace to state that diabetic retinopathy is the leading cause of visual loss in the working age population of industrialized countries and, as can be expected, the statement contains some elements of truth and some that are no longer tenable. As a matter of fact, proliferative diabetic retinopathy remains a severe sightthreatening condition for people with type 1 diabetes, who become diabetic early in life and will still be in working age when it develops. However, the most dangerous condition today is not retinal angiogenesis but the development of macular edema following breakdown of the blood-retinal barrier and that affects with equally vicious consequences patients with type 1 and 2 diabetes. Since the latter is at least 10 times more prevalent than the former, visual loss is becoming more and more the problem of elderly patients, all the more so because we lack effective, definitive treatments for macular edema. Worse, we do not know why retinal capillaries become leaky at some stage of the disease.
Another widely held opinion is that retinopathy can be prevented by optimizing blood glucose and blood pressure control. Try that in the real world and you will be shocked by the number of patients who do not reach therapeutic targets and, more so, by those who develop retinopathy in spite of attaining the goals. Yet, the incidence of severe retinopathy is decreasing among people who developed type 1 diabetes in more recent years, as attention and facilities focus more and more on day to day management of glycemia and hypertension. At any rate, the hypotheses we have on the pathways leading to glucose-induced damage will not explain why edema and/or new vessels develop at some stage, in certain areas of the retina, and only in some patients.
The search for pathogenic mechanisms that entirely explain the natural history of retinopathy and indicate a clear-cut therapeutic target (like, say, iron deficiency and replacement in iron-deficient anemia) is still unsuccessful. Laboratories around the world, with few exceptions, pursue separate lines of research on distinct substrates. Experimental work aiming at a sufficient mechanistic explanation of retinopathy genesis is often carried out by using representative cells cultured in high glucose, or in rodents which have, at best, approximate applicability to human pathology. Basic scientists may not be fully aware of the sequence and the way retinopathy presents itself in the patients' eyes, apart from archetypical fundus photographs of new vessels and hard exudates. Conversely, clinicians, when they manage to devote some preciously earned time to research,
